miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
H WuZ Gu

Abstract

miR-22 plays a great role in inhibiting cell growth, metastasis and enhanced cell apoptosis in several cancers. The purpose of this study was to investigate the functions of miR-22 in ovarian cancer. The proliferative ability was measured using CCK-8 assay. The protein expression associated with EMT and PI3K/AKT signaling biomarkers were measured by western blot. Luciferase assay applied to measure the luciferase activity. Kaplan-Meier method was performed to evaluate the overall survival rate of ovarian cancers. miR-22 was low expressed and NLRP3 was overexpressed in ovarian cancer tissues and cells, and downregulation of miR-22 was associated with poor prognosis. The expression of NLRP3 had a negative correlation with miR-22 expression in ovarian cancer. miR-22 promoted cell viability and EMT through directly binding to the 3'-UTR of NLRP3 mRNA and inhibited PI3K/AKT signaling pathway. NLRP3 partially restored functions of miR-22 on cell proliferation and EMT in ovarian cancer. miR-22 impaired cell viability and EMT by NLRP3 and inhibited PI3K/AKT signaling pathway in ovarian cancer. The newly identified miR-22/NLRP3/PI3K/AKT axis provides novel insight into the pathogenesis of ovarian cancer.

References

Oct 25, 2006·Nature Reviews. Cancer·George A Calin, Carlo M Croce
Mar 18, 2008·Immunity·Jenny P-Y TingPeter A Ward
Sep 27, 2008·Annual Review of Pathology·Yong Sun Lee, Anindya Dutta
Dec 19, 2008·The New England Journal of Medicine·Frank J Slack, Joanne B Weidhaas
Dec 8, 2011·Nature Medicine·Erik A C Wiemer
Sep 27, 2013·British Journal of Nursing : BJN·Carolyn Rooth
Nov 26, 2013·Frontiers in Immunology·Ann M JanowskiFayyaz S Sutterwala
Mar 12, 2017·Cancer Causes & Control : CCC·Rikki A CanniotoJoellen M Schildkraut
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jun 19, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yan LiuZhichao Zhu
Aug 31, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Tao ZhouChao Feng
Sep 16, 2018·Cellular and Molecular Neurobiology·Sen ShangXiaoyun Lu
Nov 6, 2018·Technology in Cancer Research & Treatment·Ying-Kui SongZhi-Jie Bian
Nov 19, 2018·Molecular Cancer·Maryam MoossaviAmirhossein Sahebkar
Jan 23, 2019·Immunology·Sarang Tartey, Thirumala-Devi Kanneganti
Jan 31, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ruifang SunChen Huang
Apr 11, 2019·Clinical Laboratory·Yuxin ShaoDianlong Zhang
Apr 25, 2019·International Journal of Molecular Sciences·Mohamed SalemChun Peng
May 1, 2019·Nature Reviews. Immunology·Karen V SwansonJenny P-Y Ting
May 19, 2019·Cancer Research·Bruna Rodrigues MuysWilson A Silva

❮ Previous
Next ❯

Citations

Jul 25, 2021·International Journal of Molecular Sciences·Fu PengXiaoqi Pan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.